These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26194766)

  • 1. Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.
    Mrozik KM; Cheong CM; Hewett D; Chow AW; Blaschuk OW; Zannettino AC; Vandyke K
    Br J Haematol; 2015 Nov; 171(3):387-99. PubMed ID: 26194766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
    Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
    J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo.
    Cheong CM; Chow AW; Fitter S; Hewett DR; Martin SK; Williams SA; To LB; Zannettino AC; Vandyke K
    Exp Cell Res; 2015 Mar; 332(1):24-38. PubMed ID: 25637218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
    Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
    Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
    Shintani Y; Fukumoto Y; Chaika N; Grandgenett PM; Hollingsworth MA; Wheelock MJ; Johnson KR
    Int J Cancer; 2008 Jan; 122(1):71-7. PubMed ID: 17721921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
    Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
    Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.
    Sharma R; Williams PJ; Gupta A; McCluskey B; Bhaskaran S; Muñoz S; Oyajobi BO
    Oncotarget; 2015 Aug; 6(25):21589-602. PubMed ID: 26009993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cadherins as novel targets for anti-cancer therapy.
    Blaschuk OW; Devemy E
    Eur J Pharmacol; 2009 Dec; 625(1-3):195-8. PubMed ID: 19836380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.
    Friend N; Noll JE; Opperman KS; Clark KC; Mrozik KM; Vandyke K; Hewett DR; Zannettino ACW
    PLoS One; 2020; 15(1):e0228408. PubMed ID: 31995627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
    Kelland L
    Curr Opin Mol Ther; 2007 Feb; 9(1):86-91. PubMed ID: 17330406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma.
    Vandyke K; Chow AW; Williams SA; To LB; Zannettino AC
    Br J Haematol; 2013 May; 161(4):499-507. PubMed ID: 23438504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial barrier stabilization by a cyclic tandem peptide targeting VE-cadherin transinteraction in vitro and in vivo.
    Heupel WM; Efthymiadis A; Schlegel N; Müller T; Baumer Y; Baumgartner W; Drenckhahn D; Waschke J
    J Cell Sci; 2009 May; 122(Pt 10):1616-25. PubMed ID: 19420236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel o-naphtoquinone inhibits N-cadherin expression and blocks melanoma cell invasion via AKT signaling.
    Montenegro RC; de Vasconcellos MC; Barbosa Gdos S; Burbano RM; Souza LG; Lemos TL; Costa-Lotufo LV; de Moraes MO
    Toxicol In Vitro; 2013 Oct; 27(7):2076-83. PubMed ID: 23912027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion.
    Burden-Gulley SM; Gates TJ; Craig SE; Lou SF; Oblander SA; Howell S; Gupta M; Brady-Kalnay SM
    Peptides; 2009 Dec; 30(12):2380-7. PubMed ID: 19765627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cadherin loss promotes experimental metastasis of squamous cell carcinoma.
    Philippova M; Pfaff D; Kyriakakis E; Buechner SA; Iezzi G; Spagnoli GC; Schoenenberger AW; Erne P; Resink TJ
    Eur J Cancer; 2013 May; 49(8):2048-58. PubMed ID: 23369463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.
    Menu E; Asosingh K; Indraccolo S; De Raeve H; Van Riet I; Van Valckenborgh E; Vande Broek I; Fujii N; Tamamura H; Van Camp B; Vanderkerken K
    Haematologica; 2006 May; 91(5):605-12. PubMed ID: 16627256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells
    Zeissig MN; Hewett DR; Panagopoulos V; Mrozik KM; To LB; Croucher PI; Zannettino ACW; Vandyke K
    Haematologica; 2021 Dec; 106(12):3176-3187. PubMed ID: 33147936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.
    Purushothaman A; Toole BP
    J Biol Chem; 2014 Feb; 289(9):5499-509. PubMed ID: 24403068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro.
    Que W; Chen J
    Mol Med Rep; 2011; 4(2):343-9. PubMed ID: 21468575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.